IRCT20230222057495N1 IRCT 2023-03-05 Aria Pharmaceutical Company In vivo study of famotidine tablet 40 mg IVSF In vivo study of famotidine tablet 40 mg, iranian product compare to the brand one on healthy volunteers 2023-04-03 anticipated 24 Complete https://irct.ir/trial/68989 interventional Randomization: Not randomized, Blinding: Not blinded, Placebo: Used, Assignment: Crossover, Purpose: Other. Bioequivalence ---. Intervention group: The study consists of two phases (taking a famotidine 40 mg tablet orally at each study time, for a total of 2 times) with a one-week washout period (when the drug is completely out of your blood). Each stage lasts for 12 hours. You must fast for 10 hours before the start of each stage. On the morning of the study, you must be present at the place of the study at 7:00 a.m. to have an angiocath installed on your arm and for 12 hours. It will remain on your hand. 5 ml of blood before taking the medicine and during sampling times in minutes: 20, 40, 60, 80, 100, 120, 150, 180, 240, 300, 360, 420, 600, 720 will be taken from you (15 times in total). With a gap of one week after receiving the first drug, the candidates must go to receive another drug and all these steps will be repeated. The total duration of participation of the candidates in both stages of this study will be a total of 24 hours, during which the candidates are covered by Pasargad insurance and financially supported by Aria Pharmaceutical Company (as the employer in this study). In the first stage of the study, you will be randomly assigned to one of the following two groups: group one consumes formula A and group two consumes formula B. Formulas A and B are products in the form of tablets produced in Belarus and Iran.. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no further information